Evidence map›Paper›PMID 7966618›Full record

ArticleJournal of virology1994

Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain.

S W Lee, H F Gallardo, E Gilboa, C Smith

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 124 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. HIV/AIDS eradication.Bioorganic & medicinal chemistry letters · 2013
    Review
  5. Novel cell and gene therapies for HIV.Cold Spring Harbor perspectives in medicine · 2012
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Gene therapy for infectious diseases.Clinical microbiology reviews · 1998
    Review
  17. Molding a peptide into an RNA site by in vivo peptide evolution.Proceedings of the National Academy of Sciences of the United States of America · 1997
    Article
  18. Anti-HIV ribozymes.Molecular biotechnology · 1997
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

S W LeeProgram of Molecular Biology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
H F Gallardo
E Gilboa
C Smith
Memorial Sloan Kettering Cancer Center · US

Funding

INTRACELLULAR IMMUNIZATION VIA TAR DECOYS IN PBLR37AI028771 · NIAID · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI GILBOA, ELI · 1992 to 2001
$623k
NIAID NIH HHS 5 R37 AI28771NIAID NIH HHS K08 AI0-121-01A1
6 · The paper itself

Abstract

Intracellular immunization is an anti-viral gene therapy strategy based on the introduction of DNA templates into cells to stably express genetic elements which inhibit viral gene expression and replication. We have recently developed an intracellular immunization strategy for human immunodeficiency virus (HIV) infection that uses RNA decoys. RNA decoys are short RNA oligonucleotides corresponding to the HIV trans activation response element (TAR) or Rev response element (RRE) sequences, which function by inhibiting the binding of the HIV regulatory proteins Tat and Rev to the authentic HIV RNA TAR and RRE regions, respectively. In this report we describe the characterization of potent RRE decoys containing the minimal 13-nucleotide primary Rev binding domain of the RRE. Using an improved tRNA cassette to express high levels of RRE transcripts in CEM cells, we found that this new generation of minimal RRE decoys were more potent inhibitors of HIV in isolated cell lines than previously described TAR or RRE decoys. CEM cells expressing RRE decoys exhibited diminished Rev function in cotransfection assays, confirming the specificity of inhibition of HIV by RRE decoys and indicating that the 13-nucleotide minimal Rev binding domain defined by using in vitro binding studies also binds Rev in vivo. Significant differences in the degree of HIV inhibition between individual CEM cell lines transduced with RRE decoy vectors which were not due to sequence alterations in the tRNA-RRE DNA template, differences in RRE decoy expression level, or endogenous variations in the resistance of CEM clonal cell lines to HIV were observed. In order to evaluate the efficacy of RRE decoys in a more realistic fashion than by comparison of individual clonal cell lines, polyclonal populations of transduced CEM cells were infected with HIV. By using a novel flow cytometric method for quantitating intracellular p24 expression, one version of the RRE decoys tested in this study was found to be capable of durably protecting polyclonal populations of CEM cells from HIV.

Indexed as

Escherichia coli ProteinsReceptors, Cell SurfaceBacterial ProteinsBase SequenceBinding SitesCell LineChemoreceptor CellsChimeraChloramphenicol O-AcetyltransferaseDNA, ViralGene ExpressionGene Products, revGenetic TherapyGenetic VectorsHIV-1HumansBacterial ProteinsChloramphenicol O-AcetyltransferaseDNA, ViralEscherichia coli ProteinsGene Products, revMembrane ProteinsOligodeoxyribonucleotidesOligoribonucleotidesReceptors, Cell Surfacerev Gene Products, Human Immunodeficiency VirusRNA, ViralTar protein, E coli

Identifiers

PMID7966618
PMCPMC237292
OpenAlexW1800005238

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.